**References**

1. Cadet J, Richard Wagner J (2013) DNA base damage by reactive oxygen species, oxidizing agents, and UV radiation. Cold Spring Harb Perspect Biol 2013: 5.

2. Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease. Nature 461: 1071-8.

3. Zhou BBS, Elledge SJ (2000) The DNA damage response: Putting checkpoints in perspective. Nature 408: 433-9.

4. Basu AK (2018) DNA damage, mutagenesis and cancer. Int J Mol Sci 2018: 19.

5. Ciccia A, Elledge SJ (2010) The DNA Damage Response: Making It Safe to Play with Knives. Mol. Cell 40: 179-204.

6. Niida H, Nakanishi M (2006) DNA damage checkpoints in mammals. Mutagenesis 21: 3-9.

7. Caldecott KW (2008) Single-strand break repair and genetic disease Nat Rev Genet 9: 619-31.

8. Chang HHY, Pannunzio NR, Adachi N, Lieber MR (2017) Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol 18: 495-506.

9. McKinnon PJ, Caldecott KW (2007) DNA strand break repair and human genetic disease. Annu Rev Genomics Hum. Genet 8: 37-55.

10. Kavanagh JN, Redmond KM, Schettino G, Prise KM (2013) DNA double strand break repair: A radiation perspective. Antioxidants Redox Signal 18: 2458-72.

11. Sancar A, Lindsey-Boltz LA, Ünsal-Kaçmaz K, Linn S (2004) Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73: 39-85.

12. Roos WP, Kaina B (2006) DNA damage-induced cell death by apoptosis. Trends Mol Med 12: 440–50.

13. Vindigni A (2017) Special issue: “At the Intersection of DNA Replication and Genome Maintenance: from Mechanisms to Therapy.” Biophys. Chem 225: 1-2.

14. Branzei D, Foiani M (2010) Maintaining genome stability at the replication fork. Nat Rev Mol Cell Biol 11: 208-19.

15. Toueille M, Hübscher U (2004) Regulation of the DNA replication fork: A way to fight genomic instability. Chromosoma 113: 113-25.

16. Toledo L, Neelsen KJ, Lukas J (2017) Replication Catastrophe: When a Checkpoint Fails because of Exhaustion. Mol. Cell 66: 735-49.

17. Demin AA, Hirota K, Tsuda M, Adamowicz M, Hailstone R, et al. (2021) XRCC1 prevents toxic PARP1 trapping during DNA base excision repair. Mol. Cell 81: 3018-30.

18. The role of PARP-1 in the repair of single stranded break (SSB) Antibody News: Novus Biologicals.

19. Nizialek E, Antonarakis ES (2020) PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date. Cancer Manag Res 2020, 12: 8105.

20. W A, D C, A P, JD S, B S, et al. (2020) Non- BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study. Clin. Cancer Res 26: 2487-96.

21. Polo SE, Jackson SP (2011) Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications. Genes Dev 25: 409.

22. Lozano R, Castro E, Aragón IM, Cendón Y, Cattrini C, et al. (2021) Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. Br J Cancer 124: 552-63.

23. Bommer UA, Thiele BJ (2004) The translationally controlled tumour protein (TCTP). Int J Biochem Cell Biol 36: 379-85.

24. Koziol MJ, Gurdon JB (2012) TCTP in development and cancer. Biochem. Res Int.

25. Bommer UA (2017) The translational controlled tumour protein TCTP: Biological functions and regulation. In Results and Problems in Cell Differentiation; Springer Verlag 64: 69-126.

26. Jojic B, Amodeo S, Ochsenreiter T (2018) The translationally controlled tumor protein TCTP is involved in cell cycle progression and heat stress response in the bloodstream form of Trypanosoma brucei. Microb Cell 5: 460-9.

27. Susini L, Besse S, Duflaut D, Lespagnol A, Beekman, C, et al. (2008) TCTP protects from apoptotic cell death by antagonizing bax function. Cell Death Differ 15: 1211-20.

28. Baylot V, Karaki S, Rocchi P (2017) TCTP Has a Crucial Role in the Different Stages of Prostate Cancer Malignant Progression. In TCTP/tpt1 - Remodeling Signaling from Stem Cell to Disease; Telerman, A., Amson, R., Eds.; Results and Problems in Cell Differentiation; Springer International Publishing: Cham 2017: 255-261.

29. Li S jie, Jia H yao, Wu D, Fan Z (2011) min Nan Fang Yi Ke Da Xue Xue Bao 31: 1560-3.

30. Chen C, Deng Y, Hua M, Xi Q, Liu R, et al. (2015) Expression and clinical role of TCTP in epithelial ovarian cancer. J. Mol. Histol 46: 145-56.

31. Bae SY, Kim HJ, Lee KJ, Lee K (2015) Translationally controlled tumor protein induces epithelial to mesenchymal transition and promotes cell migration, invasion and metastasis. Sci Rep 5: 8061.

32. Amson R, Pece S, Marine JC, Fiore PP (2013) Di; Telerman, A. TPT1/ TCTP-regulated pathways in phenotypic reprogramming. Trends Cell Biol 23: 37-46.

33. Baylot V, Katsogiannou M, Andrieu C, Taieb D, Acunzo J, et al. (2012) Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer. Mol. Ther. J. Am. Soc. Gene Ther 20: 2244-56.

34. Tuynder M, Susini L, Prieur S, Besse S, Fiucci G et al. (2002) Biological models and genes of tumor reversion: Cellular reprogramming through tpt1/TCTP and SIAH-1. Proc Natl Acad Sci USA 99: 14976-981

35. Tuynder M, Fiucci G, Prieur S, Lespagnol A, Géant A, et al. (2004) Translationally controlled tumor protein is a target of tumor reversion. Proc. Natl. Acad. Sci. USA 101: 15364-69.

36. Li F, Zhang D, Fujise K (2001) Characterization of Fortilin, a Novel Antiapoptotic Protein. J Biol Chem 276: 47542-549.

37. Telerman A, Amson R (2009) The molecular programme of tumour reversion: The steps beyond malignant transformation. Nat. Rev. Cancer 9: 206-16.

38. Bommer UA, Telerman A (2020) Dysregulation of TCTP in Biological Processes and Diseases. Cells 2020: 9.

39. Kang HS, Lee MJ, Song H, Han SH, Kim YM et al. (2001) Molecular Identification of IgE-Dependent Histamine-Releasing Factor as a B Cell Growth Factor. J Immunol 166: 6545-54.

40. Acunzo J, Baylot V, So A, Rocchi P (2014) TCTP as therapeutic target in cancers. Cancer Treat Rev 40: 760-9.

41. Karaki S, Benizri S, Mejías R, Baylot V, Branger N, et al. (2017) Lipid-oligonucleotide conjugates improve cellular uptake and efficiency of TCTP-antisense in castration-resistant prostate cancer. J Control Release 258: 1-9.

42. Katsogiannou M, Andrieu C, Baylot V, Baudot A, Dusetti NJ, et al. (2014) The functional landscape of Hsp27 reveals new cellular processes such as DNA repair and alternative splicing and proposes novel anticancer targets. Mol Cell Proteomics 13: 3585-601.

43. Amson R, Pece S, Lespagnol A, Vyas R, Mazzarol G, et al. (2012) Reciprocal repression between P53 and TCTP Nat Med 18: 91-9.

44. Zhang J, De Toledo SM, Pandey BN, Guo G, Pain D, et al. (2012) Role of the translationally controlled tumor protein in DNA damage sensing and repair. Proc Natl Acad Sci USA 2012: 109

45. Li Y, Sun H, Zhang C, Liu J, Zhang H, et al. (2017) Identification of translationally controlled tumor protein in promotion of DNA homologous recombination repair in cancer cells by affinity proteomics. Oncogene 36: 6839-49.

46. Li S, Chen M, Xiong Q, Zhang J, Cui, Z, et al. (2016) Characterization of the Translationally Controlled Tumor Protein (TCTP) Interactome Reveals Novel Binding Partners in Human Cancer Cells. J Proteome Res 15: 3741-51.

47. Li S, Ge F (2017) TCTP/tpt1 - Remodeling Signaling from Stem Cell to Disease 64: 127-36,

48. Lieber MR (2008) The mechanism of human nonhomologous DNA End joining. J Biol Chem 283: 1-5.

49. Lee JH, Paull TT (2005) ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Sci 308: 551-4.

50. ATR disruption leads to chromosomal fragmentation and early embryonic lethality.

51. Syed A, Tainer JA (2018) The MRE11-RAD50-NBS1 Complex Conducts the Orchestration of Damage Signaling and Outcomes to Stress in DNA Replication and Repair. Annu. Rev. Biochem 87: 263-94.

52. Jackson SP (2002) Sensing and repairing DNA double-strand breaks. Carcinogenesis 23: 687-96.

53. Macleod KF, Sherry N, Hannon G, Beach D, Tokino T, et al. (1995) p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 9: 935-44.

54. Hong ST, Choi KW (2013) TCTP directly regulates ATM activity to control genome stability and organ development in Drosophila melanogaster. Nat Commun 2013: 4.

55. Postow L, Ghenoiu C, Woo EM, Krutchinsky AN, et al. (2008) Funabiki, H. Ku80 removal from DNA through double strand break-induced ubiquitylation. J. Cell Biol 182: 467-79.

56. Yang K, Guo R, Xu D (2016) Non-homologous end joining: Advances and frontiers. Acta Biochim. Biophys. Sin. (Shanghai) 48: 632-40.

57. Harper JW, Elledge SJ (2007) The DNA Damage Response: Ten Years After. Mol. Cell 28: 739-45.

58. Craig EA (2018) Hsp70 at the membrane: Driving protein translocation. BMC Biol 2018: 16.

59. Dierks T, Klappa P, Wiech H, Zimmermann R (1993) The role of molecular chaperones in protein transport into the endoplasmic reticulum. Philos. Trans. R. Soc. Lond. B Biol Sci 339: 335-41.

60. Chan THM, Chen L, Guan XY (2012) Role of translationally controlled tumor protein in cancer progression. Biochem Res Int.

61. Bommer UA, Vine KL, Puri P, Engel M, Belfiore L, et al. (2017) Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin. Cell Commun. Signal 15: 1-15.

62. Wang L, Tang Y, Zhao M, Mao S, Wu L, et al. (2018) Knockdown of translationally controlled tumor protein inhibits growth, migration and invasion of lung cancer cells. Life Sci 193: 292-9.

63. Chatterjee N, Walker GC (2017) Mechanisms of DNA damage, repair, and mutagenesis. Environ Mol Mutagen 58: 235-63.

64. Jeon HJ, You SY, Park YS, Chang JW, Kim JS, et al. (2016) TCTP regulates spindle microtubule dynamics by stabilizing polar microtubules during mouse oocyte meiosis. Biochim. Biophys. Acta - Mol. Cell Res 1863: 630-7.

65. Jung J, Lee JS, Lee YS, Lee K (2019) Radiosensitivity of cancer cells is regulated by translationally controlled tumor protein. Cancers (Basel) 2019: 11.

66. Bahassi EM (2011) Polo-like kinases and DNA damage checkpoint: Beyond the traditional mitotic functions. Exp Biol Med 236: 648-57.

67. Degenhardt Y, Lampkin T (2010) Targeting polo-like kinase in cancer therapy. Clin. Cancer Res 16: 384-9.

68. Hyun SY, Hwan HI, Jang YJ (2014) Polo-like kinase-1 in DNA damage response. BMB Rep 47: 249-255.

69. Cucchi U, Gianellini LM, De Ponti A, Sola F, Alzani R, et al. (2010) Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo. Anticancer Res 30: 4973-86.

70. Bruinsma W, Aprelia M, Garciá-Santisteban I, Kool J, Xu YJ, et al. (2017) Inhibition of Polo-like kinase 1 during the DNA damage response is mediated through loss of Aurora A recruitment by Bora. Oncogene 2017, 36: 1840-48.

71. High expression of polo-like kinase 1 is associated with TP53 inactivation, DNA repair deficiency, and worse prognosis in ER positive Her2 negative breast cancer.

72. Van den Bossche J, Domen A, Peeters M, Deben C, De Pauw I, et al. (2019) Radiosensitization of non-small cell lung cancer cells by the plk1 inhibitor volasertib is dependent on the p53 status. Cancers (Basel) 2019: 11.

73. Zannini L, Delia D, Buscemi G (2014) CHK2 kinase in the DNA damage response and beyond. J Mol Cell Biol 6: 442-57.

74. Williams AB, Schumacher B (2016) p53 in the DNA-damage-repair process. Cold Spring Harb Perspect Med 2016: 6.

75. Carr MI, Jones SN (2016) Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis. Transl. Cancer Res 5: 707-24.

76. Bar J, Grelewski P, Deszcz I, Noga L, Hirnle L, et al. (2018) Association between p53 protein phosphorylated at serine 20 expression and ovarian carcinoma stem cells phenotype: correlation with clinicopathological parameters of ovarian cancer. Neoplasma 66: 801-9.

77. Caspari T (2000) Checkpoints: How to activate p53. Curr Biol 2000: 10.

78. Gannon HS, Woda BA, Jones SN (2012) ATM Phosphorylation of Mdm2 Ser394 Regulates the Amplitude and Duration of the DNA Damage Response in Mice. Cancer Cell 21: 668-79,

79. Funston G, Goh W, Wei SJ, Tng QS, Brown C, et al. (2012) Binding of translationally controlled tumour protein to the N- terminal domain of HDM2 is inhibited by Nutlin-3. PLoS One 2012: 7.

80. Boia-Ferreira M, Basílio AB, Hamasaki AE, Matsubara FH, Appel MH, et al. (2017) TCTP as a therapeutic target in melanoma treatment. Br. J. Cancer 117: 656-65.

81. Du J, Yang P, Kong F, Liu H (2017) Aberrant expression of translationally controlled tumor protein (TCTP) can lead to radioactive susceptibility and chemosensitivity in lung cancer cells. Oncotarget 8: 101922-35.

82. Malaquin N, Carrier-Leclerc A, Dessureault M, Rodier F (2015) DDR-mediated crosstalk between DNA-damaged cells and their microenvironment. Front. Genet. 2015: 5.

83. Le B, Powers GL, Tam YT, Schumacher N, Malinowski RL, et al. (2017) Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer. PLoS One 12: e0174658.